Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma

Table 1 The baseline characteristics of patients

Variables	All (n = 20)
Age, yr	68.6 ± 8.4
Gender, male : female	19:1
BMI, kg/m2	22.2 ± 4.2
ECOG PS, 0:1:	18:2
Etiology, HBV:HCV:alcohol:others	7:7:3:3
AST, IU/L	52.2 ± 38.1
ALT, IU/L	45.1 ± 26.3
T.Bil, mg/dL	0.7 ± 0.4
Alb, g/dL	3.4 ± 0.5
PT, %	82.2 ± 15.2
Plt, × 104/μL	19.7 ± 6.1
Child–Pugh score, 5:6 points	8:12
Median AFP, ng/mL (range)	268 (4.5-53000)
Intrahepatic tumor size, cm	6.6 ± 6.3
Number of intrahepatic tumors, single : multiple	3:17
Portal vein invasion, n (%)	9 (45.0)
Extrahepatic metastasis, n (%)	15 (75.0)
Previous treatment, n (%)	19 (95.0)
Initial dose of lenvatinib, 8:12 mg/d	16:4

The values represent the mean ± SD or the median (range). BMI: Body mass index; ECOG: Eastern Cooperative Oncology Group; PS: Performance Status; T.Bil: Total bilirubin; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; Alb: Albumin; PT: Prothrombin time; Plt: Platelet count; AFP: Alpha-fetoprotein.